| abstract |
A compound for use in the treatment of a polycystic liver disease is represented by Structural Formula (I): (See formula (I)) or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a polycystic liver disease in a subject in need thereof, comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods for treating a polycystic liver disease in a subject in need thereof, which respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. |